Afzanna 30mg Tablet

PRODUCT INTRODUCTION

Afzanna 30mg Tablet is a pharmaceutical formulation primarily composed of Afzaliparib, a potent medication belonging to the class of poly (ADP-ribose) polymerase (PARP) inhibitors. Afzanna is meticulously designed to target specific pathways within cancer cells, particularly those affected by mutations in BRCA genes. This medication is meticulously crafted to offer therapeutic benefits in the management of certain types of cancers, including ovarian and breast cancer. The tablet is formulated to ensure optimal bioavailability and efficacy while minimizing adverse effects.

USES OF Afzanna 30mg Tablet

Afzanna 30mg Tablet is indicated for the treatment of advanced ovarian cancer and metastatic breast cancer in patients with deleterious or suspected deleterious germline BRCA-mutated tumors. It is typically prescribed for patients who have already received prior chemotherapy or other systemic treatment regimens. Afzanna works by inhibiting PARP enzymes, thereby preventing cancer cells from repairing damaged DNA effectively. This leads to the accumulation of DNA damage, ultimately resulting in cancer cell death. The targeted action of Afzanna makes it a valuable addition to the treatment arsenal against these aggressive forms of cancer.

BENEFITS OF Afzanna 30mg Tablet

• Precision Targeting: Afzanna specifically targets cancer cells with BRCA mutations, sparing healthy cells from unnecessary damage.
• Improved Survival Rates: Clinical trials have shown that Afzanna, when used as a maintenance therapy in ovarian cancer, significantly prolongs progression-free survival compared to placebo.
• Enhanced Quality of Life: By effectively managing cancer progression, Afzanna helps in alleviating symptoms associated with advanced ovarian and metastatic breast cancer, thereby improving patients’ quality of life.
• Potential for Combination Therapy: Afzanna can be used in combination with other chemotherapy agents or targeted therapies, further enhancing its efficacy and widening treatment options for patients.

SIDE EFFECTS OF Afzanna 30mg Tablet

While Afzanna offers promising therapeutic benefits, it may also be associated with certain adverse effects. It’s crucial for patients and healthcare providers to be aware of these potential side effects:

• Hematological Toxicity: Afzanna may lead to decreased levels of red blood cells (anemia), white blood cells (neutropenia), and platelets (thrombocytopenia), increasing the risk of infections, bleeding, and fatigue.
• Gastrointestinal Disturbances: Common gastrointestinal side effects of Afzanna include nausea, vomiting, diarrhea, and abdominal pain. These symptoms can usually be managed with supportive care and medications.
• Fatigue: Patients may experience fatigue and weakness as a result of cancer treatment, including Afzanna therapy. Adequate rest, nutrition, and mild exercise can help alleviate these symptoms.
• Mild to Moderate Liver Toxicity: Afzanna may cause elevation of liver enzymes, which can indicate liver inflammation or damage. Regular monitoring of liver function tests is recommended during treatment.
• Potential for Secondary Malignancies: Long-term use of Afzanna may increase the risk of developing secondary cancers, particularly myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Close monitoring for signs and symptoms of these conditions is essential.

References